Press Releases

BrainStorm Cell Therapeutics to Present at the BIO Asia International Conference and the Wall Street Investor Forum

HACKENSACK, N.J. and PETACH TIKVAH, Israel, March 15, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Chaim Lebovits, President & Chief Executive Officer, and Dr. Ralph Kern, M.D., PhD., Chief Operating Officer & Chief Medical Officer, will provide a corporate overview at the BIO Asia International Conference, being held March 19-20 at the Grand Hyatt in Tokyo, Japan, and at the Wall Street Investor Forum, being held March 22 at the University Club of NYC, New York city.

Logo - hi-res

BIO Asia International Conference Company Presentation


Monday, March 19


11:45am (Tokyo Time – GMT+9)


Grand Hyatt Tokyo

Wall Street Investor Forum Company Presentation


Thursday, March 22


08.00am Eastern Time


University Club of NYC


About BIO Asia International Conference
The 15th Annual BIO Asia International Conference, co-hosted by the Biotechnology Innovation Organization (BIO), BioCentury and the Japan Bioindustry Association (JBA), brings together the global biotechnology and pharmaceutical industry to explore licensing and research collaborations in the current Asia-Pacific business and policy environments. Attendees can gain insights into the changes, challenges, and opportunities key opinion and policy leaders foresee for the Japanese biotech market.  The conference will take place March 19-20, 2018 at the Grand Hyatt. Tokyo. For more information:       

About Wall Street Investor Forum
Wall Street Investor Forum has conducted 85 multitrack analyst conferences in which over 1800 different NYSE/NASDAQ/OTC companies have presented and over 3000 different institutions have attended in New York, Boston & London since 1990. Although the conferences is now focused on micro/small cap companies, public companies ranging from General Electric, Microsoft Corp, Mattel, Inc., Pfizer, Inc., Biogen, Unilever, EMC, and America Online have presented. Institutions ranging from Gabelli & Company, Neuberger Berman, Wellington Management, JP Morgan Asset Management, Dreyfus, Putnam Management have attended. For more information:    

About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn® technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn® has been administered to approximately 75 patients with ALS in clinical trials conducted in the United States and Israel.  In a randomized, double-blind, placebo-controlled clinical trial conducted in the U.S., a clinically meaningful benefit was demonstrated by a higher response to NurOwn® compared with placebo. For more information, visit the company's website at

Uri Yablonka 
Chief Business Officer 
BrainStorm Cell Therapeutics Inc. 
Phone: 646-666-3188

Michael Rice 
LifeSci Advisors LLC 
Phone: 646-597-6979

Matt Middleman, M.D.
LifeSci Public Relations, LLC 
Phone: 646-627-8384


Cision View original content with multimedia:

SOURCE BrainStorm Cell Therapeutics Inc.

Email Alerts
Investor Contact
Investor FAQs
RSS Feeds